Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions.

印度制药商为了在国内外迅速发展的减肥治疗销售馅饼中分得一杯羹，已经开始开发自己版本的诺和诺德广受欢迎的Wegovy。一些分析师预测，到本世纪末，减肥市场将达到每年1000亿美元或更多，全球最大的仿制药制造商Sun Pharma、Cipla、Reddy博士和Lupin的高管都表示，他们已经开始研发Wegovy版本。

Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise. U.S. rival Eli Lilly likewise has been unable to meet demand for its weight-loss drugs Zepbound and Mounjaro.

由于全球肥胖率创纪录，人们正在寻找更简单的饮食和运动替代品，诺和诺德公司（NovoNordisk）无法生产足够的Wegovy来满足已经推出的六个以上国家的需求。U、 同样，美国竞争对手礼来公司（EliLilly）也无法满足其减肥药Zepbound和Mounjaro的需求。

Novo has not provided a clear timeline for introducing Wegovy globally, but told Reuters it aims to launch in India in 2026. The move by Indian drugmakers could go a long way toward improving global access to weight-loss drugs and make them far more affordable, analysts said. 'We expect volume expansion to increase multi-fold by the time patent expires, which is a few years from now,' Systematix analyst Vishal Manchanda said.

Novo没有提供在全球推出Wegovy的明确时间表，但告诉路透社，它的目标是2026年在印度推出。分析人士说，印度制药商的这一举措可能大大有助于改善全球减肥药物的获取，并使其价格更加实惠Systematix分析师维沙尔·曼昌达（VishalManchanda）说，我们预计，到专利到期时，即几年后，销量将增长数倍。

'They will also be available at a much lower price by generic drugmakers.' Industry insiders agreed. 'There is big potential in India... given the lifestyle choices,' Cipla Global CEO Umang Vohra said in a post-earnings call in January. India has high obesity rates, especially among women, and has the world's second highest number of people with type 2 diabetes, trailing only China.

“仿制药制造商也将以低得多的价格提供。”业内人士表示同意印度有很大的潜力。。。Cipla全球首席执行官乌曼·沃拉（UmangVohra）在1月份的一次财报电话会议上说，考虑到生活方式的选择。印度的肥胖率很高，尤其是女性，并且是世界上第二高的2型糖尿病患者，仅次于中国。

Around 11% of adults in India will be obese by 2035, according to the World Obesity Federation Atlas. Novo's patents for Wegovy, given as a weekly injection, expire i.

根据世界肥胖联合会地图集，到2035年，印度大约11%的成年人将肥胖。Novo的Wegovy专利（每周注射一次）将于1月到期。